Company Filing History:
Years Active: 2014
Title: The Innovative Contributions of Anthony Mazurek
Introduction
Anthony Mazurek is a notable inventor based in Cold Spring Harbor, NY (US). He has made significant contributions to the field of cancer research, particularly in the development of therapies for chemotherapy-resistant leukemia. His work is characterized by a strong focus on RNA interference (RNAi) technologies.
Latest Patents
Mazurek holds a patent titled "Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers." This patent describes a mosaic mouse model designed to evaluate the effectiveness of short hairpin RNA (shRNA) in vivo for reducing the survival of cancer cells associated with chemotherapy-resistant leukemia. The model involves transplanting a syngeneic mouse recipient with tet-on competent leukemia cells that carry a bicistronic nucleic acid construct. This construct includes a promoter linked to a fusion gene related to chemotherapy-resistant leukemia and a sequence encoding a reverse tet-transactivator protein, allowing for co-expression of both coding sequences from the promoter. Additionally, the patent outlines methods for treating soft tissue cancers.
Career Highlights
Mazurek is affiliated with Cold Spring Harbor Laboratory, where he conducts his research. His work has been instrumental in advancing the understanding of RNAi and its applications in cancer therapy. His innovative approaches have garnered attention in the scientific community.
Collaborations
Mazurek has collaborated with esteemed colleagues such as Bruce W. Stillman and Scott William Lowe. These partnerships have further enriched his research and contributed to the development of effective cancer treatments.
Conclusion
Anthony Mazurek's contributions to cancer research through his innovative patent and collaborative efforts highlight the importance of RNAi in developing therapies for challenging medical conditions. His work continues to inspire advancements in the field of oncology.